NetraMark Holdings Inc., an AI company specializing in clinical trials, and AlgoTherapeutix SAS (AlgoTx), a biotech company developing therapies for chemotherapy-induced peripheral neuropathy (CIPN), have formed a partnership. NetraMark will utilize its NetraAI platform to analyze patient data from AlgoTx’s ATX01 program, aiming to identify responder characteristics and refine future trial design. This collaboration seeks to accelerate the development of effective CIPN treatments.
This partnership is notable because it combines AlgoTx’s focus on a significant unmet medical need—CIPN, a painful side effect of chemotherapy—with NetraMark’s advanced AI capabilities. By identifying specific patient personas and predicting responses to ATX01, the collaboration could significantly improve the efficiency of clinical trials. This could lead to faster development of a much-needed CIPN treatment, bringing relief to patients sooner.
NetraMark’s NetraAI platform will analyze data from AlgoTx’s ATX01 program, focusing on drug and placebo responses. The platform’s goal is to create customized models and tools that will allow AlgoTx to refine patient selection and optimize future trial design. This approach seeks to move beyond traditional AI by providing explainable and regulator-ready insights.
This collaboration marks a potentially significant step in CIPN treatment development. The integration of advanced AI into clinical trials could improve the efficiency and effectiveness of drug development, potentially leading to faster approval and market entry for promising therapies like ATX01. Ultimately, this could translate to improved outcomes and quality of life for patients suffering from CIPN.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
